Literature DB >> 23106407

A/H5N1 prepandemic influenza vaccine (Vepacel®): a guide to its use.

Gillian M Keating1, Greg L Plosker, Katherine A Lyseng-Williamson.   

Abstract

Vepacel® is a prepandemic influenza vaccine (whole virion, Vero cell-derived, inactivated) containing antigen of H5N1 strain A/Vietnam/1203/2004 and is approved for use in the EU. Clinical immunogenicity studies with the vaccine have demonstrated good functional neutralizing antibody responses against the vaccine strain (A/Vietnam/1203/2004), and cross-reactivity against H5N1 strains from other clades. In general, adverse events observed in clinical immunogenicity studies with a whole virions H5N1 vaccine (A/Vietnam/1203/2004) were similar to those reported with non-adjuvanted, inactivated, split virion seasonal influenza vaccines.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23106407     DOI: 10.1007/bf03261899

Source DB:  PubMed          Journal:  BioDrugs        ISSN: 1173-8804            Impact factor:   5.807


  4 in total

Review 1.  Clinical vaccine development for H5N1 influenza.

Authors:  Christopher H Clegg; Joseph A Rininger; Susan L Baldwin
Journal:  Expert Rev Vaccines       Date:  2013-07       Impact factor: 5.217

2.  An anti-H5N1 influenza virus FcDART antibody is a highly efficacious therapeutic agent and prophylactic against H5N1 influenza virus infection.

Authors:  Mark Zanin; Zhen-Yong Keck; G Jonah Rainey; Chia-Ying Kao Lam; Adrianus C M Boon; Adam Rubrum; Daniel Darnell; Sook-San Wong; Yolanda Griffin; Jinming Xia; Robert G Webster; Richard Webby; Syd Johnson; Steven Foung
Journal:  J Virol       Date:  2015-02-11       Impact factor: 5.103

Review 3.  A comprehensive overview of vaccines developed for pandemic viral pathogens over the past two decades including those in clinical trials for the current novel SARS-CoV-2.

Authors:  Kannan Damodharan; Gandarvakottai Senthilkumar Arumugam; Suresh Ganesan; Mukesh Doble; Sathiah Thennarasu
Journal:  RSC Adv       Date:  2021-06-08       Impact factor: 4.036

4.  Market implementation of the MVA platform for pre-pandemic and pandemic influenza vaccines: A quantitative key opinion leader analysis.

Authors:  Bahar Ramezanpour; Esther S Pronker; Joost H C M Kreijtz; Albert D M E Osterhaus; E Claassen
Journal:  Vaccine       Date:  2015-06-03       Impact factor: 3.641

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.